A traditional chinese medicine formulation consisting of Rhizoma corydalis and Rhizoma curcumae exerts synergistic anti-tumor activity

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 1077-1083

  Gao, Jian Li ^a   He, Tong Chuan ^b   Li, Ying Bo ^a   Wang, Yi Tao ^a  

^a University of Macau   (Macao)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Combination effect; Synergy; Yanhusuo San

Indexed keywords

ANTINEOPLASTIC AGENT; CHINESE DRUG; CYTOCHROME C; EZHU; MITOGEN ACTIVATED PROTEIN KINASE 1; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; YANHUSUO;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL INVASION; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CHINESE MEDICINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; DRUG POTENTIATION; ENZYME RELEASE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CORYDALIS; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; PLANT EXTRACTS; PLANTS, MEDICINAL; TUMOR CELLS, CULTURED;

EID: 70449394399     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000539     Document Type: Article

References (32)

1. Baxevanis CN, Perez SA and Papamichail M: Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58: 317-324, 2009.
2. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681, 2006.
3. Czuczwar SJ, Kaplanski J, Swiderska-Dziewit G, et al: Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. Expert Opin Drug Metab Toxicol (In press).
4. Chou TC: Preclinical versus clinical drug combination studies. Leuk Lymphoma 49: 2059-2080, 2008.
5. Jin HJ, Siwak EB, Smith R, et al: Very strong synergy between modified RANTES and gp41 binding peptides leads to potent anti-HIV-1 activity. Antimicrob Agents Chemother (In press).
6. Bell A: Antimalarial drug synergism and antagonism: mechanistic and clinical significance. FEMS Microbiol Lett 253: 171-184, 2005.
7. Uppuluri P, Nett J, Heitman J, et al: Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 52: 1127-1132, 2008.
8. Zhao L, Wientjes MG and Au JL-S: Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10: 7994-8004, 2004.
9. Wagnera H and Ulrich-Merzenich G: Synergy research: Approaching a new generation of phytopharmaceuticals. Phytomedicine 16: 97-110, 2009.
10. Ung CY, Li H, Cao ZW, et al: Are herb-pairs of traditional Chinese medicine distinguishable from others? Pattern analysis and artificial intelligence classification study of traditionally defined herbal properties. J Ethnopharmacol 111: 371-377, 2007.
11. Gao JL, Shi JM, He K, et al: Yanhusuo extract inhibits metastasis of breast cancer cells by modulating mitogen-activated protein kinase (MAPK) signaling pathways. Oncol Rep 20: 819-824, 2008.
12. Xiao Y, Yang FQ, Li SP, et al: Furanodiene induces G2/M cell cycle arrest and apoptosis through MAPK signaling and mitochondria-caspase pathway in human hepatocellular carcinoma cells. Cancer Biol Ther 6: 1044-1050, 2007.
13. Xiao Y, Yang FQ, Li SP, et al: Essential oil of Curcuma wenyujin induces apoptosis in human hepatoma cells. World J Gastroenterol 14: 4309-4318, 2008.
14. Yang FQ, Wang YT and Li SP: Simultaneous determination of 11 characteristic components in three species of Curcuma rhizomes using pressurized liquid extraction and high-performance liquid chromatography. J Chromatogr A 1134: 226-231, 2006.
15. Ding B, Zhou TT, Fan GR, et al: Qualitative and quantitative determination of ten alkaloids in traditional Chinese medicine Corydalis yanhusuo W.T. Wang by LC-MS/MS and LC-DAD. J Pharm Biomed Anal 45: 219-226, 2007.
16. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
17. Takabatake D, Fujita T, Shien T, et al: Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231). Int J Cancer 120: 181-188, 2007.
18. Wagenpfeil S, Treiber U and Lehmer A: Statistical analysis of combined dose effects for experiments with two agents. Artif Intell Med 37: 65-71, 2006.
19. Naruse T, Nishida Y and Ishiguro N: Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells. Biomed Pharmacother 61: 338-346, 2007.
20. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy chemotherapy: the concept of additivity. Int J Oncol Biol Phys Radiat 5: 85-93, 1979.
21. Sa F, Gao JL, Fung KP, et al: Anti-proliferative and pro-apoptotic effect of Smilax glabra Roxb. extract on hepatoma cell lines. Chem Biol Interact 171: 1-14, 2008.
22. Tallarida RJ: Drug synergism: its detection and applications. J Pharmacol Exp Ther 298: 865-872, 2001.
23. Yoshizawa J, Takizawa A, Takeuchi O, et al: Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemother Pharmacol (In press).
24. McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/ MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
25. Medina V, Edmonds B, Young GP, et al: Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57: 3697-3707, 1999.
26. Kang MH, Wan Z, Kang YH, et al: Mechanism of synergy of N-(4-hydroxyphenyl) retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100: 580-595, 2008.
27. Yanovich S and Preston L: Effects of verapamil on daunomycin cellular retention and cytotoxicity in P388 leukemic cells. Cancer Res 44: 1743-1747, 1984.
28. Katayama K, Yoshioka S, Tsukahara S, et al: Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 6: 2092-2102, 2007.
29. Chearwae W, Anuchapreeda S, Nandigama K, et al: Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biomed Pharmacother 68: 2043-2052, 2004.
30. Limtrakul P, Anuchapreeda S and Buddhasukh D: Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 4: 13-18, 2004.
31. Lin HL, Liu TY, Wu CW, et al: Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel. Br J Cancer 81: 416-422, 1999.
32. He L and Liu GQ: Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier. Acta Pharmacol Sin 23: 423-429, 2002.